LRRK2 Cohort Consortium
The Michael J. Fox Foundation (MJFF) is pioneering an innovative approach around the LRRK2 gene in an effort to streamline and orchestrate drug development against this promising target for Parkinson's disease (PD) drug development. The MJFF-led LRRK2 Cohort Consortium brings research groups together early on -- sharing resources, troubleshooting common problems, and identifying best resources -- to speed collective efforts to move LRRK2 toward practical therapeutic relevance for patients.
The Consortium follows standardized data acquisition protocols to ensure that tests and assessments conducted at multiple sites can be pooled. Cross-sectional data and samples acquired from study participants are included in a comprehensive Parkinson's database and bio-repository, which is available to the scientific community to conduct research on novel PD biomarkers and will be updated on a quarterly basis throughout the duration of the study. The Consortium aims to complement PPMI to produce a comprehensive dataset available for biomarker discovery work throughout the PD community.
Available Biospecimens and Data*
|Clinical Data||Whole Blood||Plasma||Serum||RNA||Urine||CSF|
|LRRK2+ PD subjects||465||114||114||115||115||101||26|
|LRRK2+ without PD||353||90||90||91||91||89||29|
*Available resources as of May 6, 2013. Numbers refer to submissions from unique individuals. Typical submissions include: clinical data, 6 ml whole blood (frozen without processing), 10 ml whole blood for plasma, 10 ml whole blood for serum, 2.5 ml whole blood for RNA extraction, 10 ml urine; 10 ml cerebrospinal fluid.
Recruitment is ongoing and sites continue to collect samples and clinical data. The next cut of data and samples will be released on October 1, 2013.
View a list of publications and presentations utilizing the resources.